Telix to acquire ITM in $1.65bn radiopharmaceutical deal
Telix Pharmaceuticals has signed a binding agreement to acquire ITM Isotope Technologies Munich SE in a transaction valued at US$1.65 billion upfront on a cash-free, debt-free basis, with up to US$700 million in additional contingent payments tied to regulatory approvals and commercial milestones for ITM's lead therapeutic candidate.
The deal, announced on 21 September 2026, will see ITM shareholders receive approximately US$1.25 billion in Telix shares, priced at a 30-day trailing volume-weighted average of US$11.84, released as Nasdaq ADRs after escrow periods expire. Telix will also assume US$302 million of net debt at closing. Upon completion, Telix shareholders will hold around 76.3% of the enlarged group, with former ITM shareholders holding the remaining 23.7%.
The deal
ITM, headquartered in Munich, is the only producer of globally scaled commercial-grade lutetium-177 (177Lu) and supplies isotopes to both approved radiopharmaceutical products and assets in clinical development. The company reported revenue of US$273 million in 2025, growing at a compound annual rate of 40% between 2021 and 2025, and its isotope manufacturing operations are already profitable and cash-generative.
The strategic rationale for Telix centres on securing supply-chain control over the isotopes underpinning its therapeutic pipeline, which includes three pivotal-stage assets in prostate cancer, recurrent glioblastoma and kidney cancer. ITM's distribution network spans more than 65 countries, and a 15-year exclusive supply agreement with Bruce Power in Canada provides long-term access to reactor irradiation capacity for 177Lu production.
ITM's own pipeline adds a near-term commercial catalyst. Its lead candidate, ITM-11 (177Lu-edotreotide), has completed a Phase 3 trial in gastroenteropancreatic neuroendocrine tumours (GEP-NETs) with results published in The Lancet in July 2026, and a second Phase 3 study covering a further indication is fully enrolled, with an interim analysis expected in the first half of 2027. The contingent consideration of up to US$700 million is structured around three FDA approval milestones for different NET indications by December 2031, and net global sales of ITM-11 exceeding US$150 million in 2030.
Market context
The transaction reflects accelerating consolidation in the radiopharmaceutical sector, where competition for isotope supply and manufacturing capacity has intensified alongside growing clinical and commercial validation of targeted radionuclide therapy. Novartis's Lutathera, also a 177Lu-SSTR-targeted agent for NETs, established the commercial template that ITM-11 seeks to compete against. The global nuclear medicine market is forecast to exceed US$41 billion by 2034, according to figures cited by the companies.
Telix managing director Christian Behrenbruch said the merger positions the group "at the forefront of the consolidation that is occurring as the industry matures" and described ITM as "the leader in radioisotope production, with deep scientific expertise and a track record of value-adding innovation."
The combined entity is expected to report pro forma 2026 revenue and income exceeding US$1.3 billion, based on management estimates, with positive EBITDA contribution targeted from 2027. The transaction requires approval from Telix shareholders at an extraordinary general meeting expected in November 2026, along with customary regulatory clearances, and is expected to close before the end of the financial year.